ProKidney Corp. (PROK) Insider Trading Activity

NASDAQ$1.98
Market Cap
$557.19M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
123 of 888
Rank in Industry
82 of 508

PROK Insider Trading Activity

PROK Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$1,519,323
7
70
Sells
$1,135,794
3
30

Related Transactions

Control Empresarial de Capitales S.A. de C.V.Add'l Rep. Persons-see Ex.99-1
7
$1.52M
0
$0
$1.52M
Weber Darin J.Chief Regulatory Officer
0
$0
1
$312,510
$-312,510
Pereira Brian JGdirector
0
$0
2
$823,284
$-823,284

About ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Insider Activity of ProKidney Corp.

Over the last 12 months, insiders at ProKidney Corp. have bought $1.52M and sold $1.14M worth of ProKidney Corp. stock.

On average, over the past 5 years, insiders at ProKidney Corp. have bought $25.53M and sold $7.46M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Control Empresarial de Capitales S.A. de C.V. (Add'l Rep. Persons-see Ex.99-1) — $1.52M.

The last purchase of 387,393 shares for transaction amount of $276,366 was made by Control Empresarial de Capitales S.A. de C.V. (Add'l Rep. Persons‑see Ex.99‑1) on 2025‑04‑22.

List of Insider Buy and Sell Transactions, ProKidney Corp.

2025-11-13SalePereira Brian JGdirector
54,333
0.0201%
$2.37
$128,769
-3.29%
2025-11-12SalePereira Brian JGdirector
255,026
0.0804%
$2.72
$694,515
-17.54%
2025-07-08SaleWeber Darin J.Chief Regulatory Officer
103,480
0.0285%
$3.02
$312,510
-34.32%
2025-04-22PurchaseControl Empresarial de Capitales S.A. de C.V.Add'l Rep. Persons-see Ex.99-1
387,393
0.1595%
$0.71
$276,366
+205.70%
2025-04-17PurchaseControl Empresarial de Capitales S.A. de C.V.Add'l Rep. Persons-see Ex.99-1
25,000
0.0108%
$0.75
$18,690
+188.28%
2025-04-16PurchaseControl Empresarial de Capitales S.A. de C.V.Add'l Rep. Persons-see Ex.99-1
100,000
0.0432%
$0.75
$74,820
+186.47%
2025-04-15PurchaseControl Empresarial de Capitales S.A. de C.V.Add'l Rep. Persons-see Ex.99-1
468,000
0.1881%
$0.70
$326,009
+221.08%
2025-04-14PurchaseControl Empresarial de Capitales S.A. de C.V.Add'l Rep. Persons-see Ex.99-1
268,105
0.1123%
$0.73
$194,591
+208.11%
2025-04-11PurchaseControl Empresarial de Capitales S.A. de C.V.Add'l Rep. Persons-see Ex.99-1
1,900
0.0007%
$0.61
$1,155
+211.77%
2025-04-10PurchaseControl Empresarial de Capitales S.A. de C.V.Add'l Rep. Persons-see Ex.99-1
1.03M
0.3622%
$0.61
$627,692
+271.64%
2024-09-19SaleWeber Darin J.Chief Regulatory Officer
16,412
0.007%
$2.50
$41,030
-30.54%
2024-07-26SaleWeber Darin J.Chief Regulatory Officer
826
0.0004%
$2.50
$2,065
-32.24%
2024-06-18SaleWeber Darin J.Chief Regulatory Officer
17,238
0.0083%
$2.82
$48,616
-36.57%
2024-06-13PurchaseLegorreta Pablo G.
22.62M
9.3818%
$2.42
$54.74M
-42.76%
2024-06-11PurchaseControl Empresarial de Capitales S.A. de C.V.Add'l Rep. Persons-see Ex.99-1
8.26M
3.4281%
$2.42
$20M
-29.55%
2024-05-20SaleWeber Darin J.Chief Regulatory Officer
17,238
0.0121%
$4.08
$70,386
-53.74%
2024-04-22SaleWeber Darin J.SVP of Regulatory Development
16,438
0.0071%
$2.51
$41,315
-30.33%
2024-04-18SaleWeber Darin J.SVP of Regulatory Development
800
0.0003%
$2.54
$2,028
-19.79%
2024-04-16SaleWeber Darin J.SVP of Regulatory Development
17,238
0.0074%
$2.50
$43,095
-28.68%
2024-04-12SaleWeber Darin J.SVP of Regulatory Development
84,103
0.0249%
$1.73
$145,498
+12.86%
Total: 63
*Gray background shows transactions not older than one year

Insider Historical Profitability

19.77%
Control Empresarial de Capitales S.A. de C.V.Add'l Rep. Persons-see Ex.99-1
73842723
26.2403%
$146.21M130
+27.01%
Pereira Brian JGdirector
0
0%
$002
Weber Darin J.Chief Regulatory Officer
0
0%
$0010
Legorreta Pablo G.
22617909
8.0374%
$44.78M10
<0.0001%
Cowen Aaron10 percent owner
6280175
2.2317%
$12.43M30
+26.12%
Palihapitiya Chamath
0
0%
$0034
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$3,611,891
113
13.40%
$578.31M
$860,541,348
82
-5.10%
$518.06M
$63,049,419
31
2.87%
$534.69M
$112,238,340
19
39.16%
$482.32M
$3,556,951
18
9.64%
$530.03M
$46,858,891
18
-11.58%
$573.63M
$59,102,045
17
8.52%
$584.82M
$7,254,955
14
20.70%
$622.95M
$8,069,667
13
-13.57%
$500.69M
$19,167,169
10
28.48%
$575.2M
$140,543,039
10
0.77%
$599.66M
ProKidney Corp.
(PROK)
$75,069,528
10
19.77%
$557.19M
$94,000,000
7
-20.84%
$595.69M
$49,165,200
7
12.92%
$658.1M
$1,746,565
4
-29.05%
$528.02M
$58,352
4
-43.78%
$499.96M
$7,234,370
3
-3.34%
$604.62M
$2,857,000
2
-5.23%
$494.27M
$300,016
1
-50.33%
$548.94M

PROK Institutional Investors: Active Positions

Increased Positions33+44%6M+16.04%
Decreased Positions35-46.67%5M-15.36%
New Positions18New4MNew
Sold Out Positions18Sold Out1MSold Out
Total Postitions73-2.67%35M+0.68%

PROK Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Suvretta Capital Management, Llc$27,521.008.69%12.34M00%2025-09-30
Morgan Stanley$15,046.004.75%6.75M+759,481+12.68%2025-09-30
Bleichroeder Lp$4,460.001.41%2M00%2025-09-30
Millennium Management Llc$4,363.001.38%1.96M+2MNew2025-09-30
Vanguard Group Inc$3,488.001.1%1.56M-3,752-0.24%2025-09-30
Blackrock, Inc.$2,848.000.9%1.28M-487,404-27.62%2025-09-30
Geode Capital Management, Llc$2,446.000.77%1.1M+84,662+8.37%2025-09-30
Brown University$2,230.000.7%1M00%2025-09-30
Hennion & Walsh Asset Management, Inc.$2,051.000.65%919,903-16,923-1.81%2025-09-30
Bank Of America Corp /De/$1,474.000.47%660,864-185,290-21.9%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.